Biocon Limited · NSE:BIOCON

Biocon — Q3 FY26 Earnings Presentation

16 slides from Biocon's earnings presentation, Feb 13, 2026

  1. Slide 1: Exchange filing cover letter for Q3 FY26 earnings presentation

    Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2025-26/176 February 13, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of

  2. Slide 2: Biocon Limited Q3 FY26 Earnings Call

    Biocon Limited Q3 FY26 Earnings Call 13 – February – 2 0 2 6

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s

  4. Slide 4: Chairperson Opening Remarks

    Chairperson Opening Remarks

  5. Slide 5: Opening Remarks: Q3 FY26 Performance Overview

    Opening Remarks: Q3 FY26 Performance Overview A Pivotal Transformation Underway o Biocon among pioneers building India's global biologics and biosimilars ecosystem o Focus on non-communicable diseases: diabetes, oncology, immunology and metabolic care Unified Global Biopharma Platform o Simplified g

  6. Slide 6: Q3 FY26 Financial Highlights

    Q3 FY26 Financial Highlights

  7. Slide 7: Financial Highlights – Q3 FY26

    Financial Highlights – Q3 FY26 In ₹ Cr Q3 FY26 Q3 FY25 Q2 FY26 YoY% QoQ% Generics 851 686 774 24 10 Biosimilars 2,497 2,289 2,721 9 (8) CRDMO 917 944 911 (3) 1 Revenue from Operations 4,173 3,821 4,296 9 (3) Total Revenue 4,290 3,856 4,389 11 (2) Core EBITDA1 1,221 1,007 1,218 21 0 % Margin 29 26 28

  8. Slide 8: Biosimilars

    Biosimilars

  9. Slide 9: Biocon Biologics: Q3 FY26 Business Performance update

    Biocon Biologics: Q3 FY26 Business Performance update North America – Strong Q3 led by Oncology & Immunology o Yesintek continues to gain strong commercial traction with a market Q3 Q3 Q2 QoQ In ₹ Cr YoY% leading position among biosimilars FY26 FY25 FY26 % o Expanded Civica partnership enabling laun

  10. Slide 10: Generics

    Generics

  11. Slide 11: Biocon Generics: Q3 FY26 Business Performance update

    Biocon Generics: Q3 FY26 Business Performance update Strong Revenue Momentum Q3 Q3 Q2 In ₹ Cr YoY% QoQ% o Ongoing gLiraglutide launches across EU markets FY26 FY25 FY26 o Improved performance of base generic formulations business Segment 851 686 774 24 10 Revenue Pipeline Progress and Key Regulatory

  12. Slide 12: CRDMO

    CRDMO

  13. Slide 13: CRDMO: Q3 FY26 Business Performance update

    CRDMO: Q3 FY26 Business Performance update Business Performance Q3 Q3 Q2 In ₹ Cr YoY% QoQ% o 9MFY26 revenue up 3% YoY, Q3 revenue down 3% YoY FY26 FY25 FY26 o Performance impacted by challenges at one manufacturing customer Segment 917 944 911 (3) 1 – transient and should normalize over time Revenue

  14. Slide 14: Concluding Remarks

    Concluding Remarks

  15. Slide 15: Concluding Remarks: Q3 FY26

    Concluding Remarks: Q3 FY26 Strong progress across product portfolio and pipeline, go-to-market execution and building a resilient, long-term operating model Differentiated portfolio spanning biosimilars, insulins, generics and peptides, including GLP-1s Focus on sustainable growth, margin expansion

  16. Slide 16: Q&A

    $ Biocon REACH EXPANDING ACCESS PROPELLING GROWTH Q&A

Biocon — Q3 FY26 Earnings Presentation on 6ix